WallStSmart

Abbott Laboratories (ABT)vsCytek Biosciences Inc (CTKB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 21900% more annual revenue ($44.33B vs $201.49M). ABT leads profitability with a 14.7% profit margin vs -33.0%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

CTKB

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 3.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for CTKB.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

CTKB4 strengths · Avg: 9.5/10
EPS GrowthGrowth
73.5%10/10

Earnings expanding 73.5% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.1910/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

CTKB4 concerns · Avg: 2.5/10
Market CapQuality
$575.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-18.0%2/10

ROE of -18.0% — below average capital efficiency

Free Cash FlowQuality
$-1.77M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : CTKB

The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : CTKB

The primary concerns for CTKB are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while CTKB is a turnaround play — different risk/reward profiles.

CTKB carries more volatility with a beta of 1.31 — expect wider price swings.

CTKB is growing revenue faster at 8.1% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Cytek Biosciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, providing state-of-the-art cell analysis solutions to the life sciences industry. The company's advanced technologies facilitate comprehensive cellular analyses that are crucial for research in immunology, cancer diagnostics, and drug development. With a commitment to innovation and excellence in customer service, Cytek has solidified its status as a key contributor in the biotechnology sector, addressing the growing need for precise cell analysis tools. Boasting a diverse product portfolio and a robust market position, the company continues to drive advancements in the rapidly evolving field of cell biology research.

Want to dig deeper into these stocks?